CAS: 1420-55-9; Thiethylperazine

上下游产品

3-(N-methylpiperazinyl)propyl chloride 2-(ethylthio)-10H-phenothiazine 2-ethylmercapto-phenothiazine-10-carboxylic acid-[3-(4-methyl-piperazino)-propyl ester] (3-ethylsulfanyl-phenyl)-phenyl-amine

📜3-(乙硫基)-N-苯基苯胺置于sodium Hydroxide,碘,Sulfur,甲苯体系中,化学反应生成乙巯匹拉嗪
参考文献:苯并噻嗪-盖比(shenthesen Auf Dem Phenothiazin-Gebiet).2. Mitteilung.N-取代巯基吩噻嗪衍生物
标题:苯并噻嗪-盖比(shenthesen Auf Dem Phenothiazin-Gebiet).2. Mitteilung.N-取代巯基吩噻嗪衍生物
摘要:描述了一系列3-巯基吩噻嗪的药理学上令人感兴趣的n-取代衍生物的合成.
Doi:10.1002/hlca.19580410420

专利信息

专利号:US-2008214827-A1
优先权日:2004-02-03
标 题:Synthesis of Cyanoimino-Benzoimidazoles
发明人：GOEHRING R RICHARD; WHITEHEAD JOHN; SHAO BIN
权利人:EURO CELTIQUE SA
摘要:Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.

专利号:WO-0054773-A1
优先权日:1999-03-12
标题:Dopamine agonists in combination with nitric oxide donors, compositions and methods of use
发明人：GARVEY DAVID S
权利人:NITROMED INC; GARVEY DAVID S
摘要:The present invention is directed to novel compositions comprising at least one dopamine agonist in combination with at least one nitric oxide donor (i.e. compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are substrates for nitric oxide synthase). The novel compositions may optionally comprise at least one therapeutic agent, such as, a vasoactive agent, an antimetic agent, and mixtures thereof. The dopamine agonist is preferably apomorphine. The present invention is also directed to methods for treating and/or preventing sexual dysfunctions and/or enhancing sexual responses in patients. In other embodiments, the present invention is directed to methods treating or preventing neurodegenerative diseases, mitochondrial diseases, spinal cord injury, central or psychostimulant addiction, senile dementia, circulatory disorders, cardiovascular disorders, hyperprolactinaemia or myopia. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.

专利号:US-7935686-B2
优先权日:2004-11-03
标 题 :Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
发明人：GALLOP MARK A
权利人:XENOPORT INC
摘要:Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.

专利号:EP-3103803-B1
优先权日:2008-10-27
标 题 :Intermediates for the synthesis of mtor kinase inhibitors

专利号:CA-2555219-A1
优先权日:2004-02-03
标 题 :Synthesis of cyanoimino-benzoimidazoles

专利号:US-7566738-B2
优先权日:2004-11-03
标题 :Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
发明人：GALLOP MARK A
权利人:XENOPORT INC
摘要:Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof, pharmaceutical compositions of 3-aminopropylsulfinic acid and analogs thereof, methods of making prodrugs of 3-aminopropylsulfinic acid and analogs thereof, methods of using prodrugs of 3-aminopropylsulfinic acid and analogs thereof, and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylsulfinic acid and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed.